[HTML][HTML] Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
E Petersen, M Koopmans, U Go, DH Hamer… - The Lancet infectious …, 2020 - thelancet.com
The objective of this Personal View is to compare transmissibility, hospitalisation, and
mortality rates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with …
mortality rates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with …
Management of osteoporosis in patients living with HIV—a systematic review and meta-analysis
J Starup-Linde, SB Rosendahl… - JAIDS Journal of …, 2020 - journals.lww.com
Objective: Osteoporosis is reported as a common comorbidity in patients living with HIV
(PLHIV). The aim of this systematic review and meta-analysis is to assess the evidence on …
(PLHIV). The aim of this systematic review and meta-analysis is to assess the evidence on …
[HTML][HTML] Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
JD Gunst, NB Staerke, MH Pahus, LH Kristensen… - …, 2021 - thelancet.com
Background The trans-membrane protease serine 2 (TMPRSS2) is essential for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy …
[HTML][HTML] Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection
CL Hvas, SMD Jørgensen, SP Jørgensen, M Storgaard… - Gastroenterology, 2019 - Elsevier
Background & Aims Fecal microbiota transplantation (FMT) is recommended for treatment of
recurrent Clostridium difficile infection (rCDI). We performed a single-center randomized trial …
recurrent Clostridium difficile infection (rCDI). We performed a single-center randomized trial …
Existing data sources for clinical epidemiology: the Danish Study Group of Infections of the Brain Database (DASGIB)
J Bodilsen, L Larsen, CT Brandt, L Wiese… - Clinical …, 2021 - Taylor & Francis
Central nervous system (CNS) infections are rare diseases that are associated with
considerable morbidity and mortality. Increased knowledge based on contemporary data is …
considerable morbidity and mortality. Increased knowledge based on contemporary data is …
[HTML][HTML] The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study
P Comstedt, M Storgaard, AT Lassen - Scandinavian journal of trauma …, 2009 - Springer
Background Sepsis is an infection which has evoked a systemic inflammatory response.
Clinically, the Systemic Inflammatory Response Syndrome (SIRS) is identified by two or …
Clinically, the Systemic Inflammatory Response Syndrome (SIRS) is identified by two or …
Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial
KB Kristoffersen, OS Søgaard, C Wejse… - Clinical Microbiology …, 2009 - Wiley Online Library
Clin Microbiol Infect Abstract Recent studies have suggested that procalcitonin (PCT) is a
safe marker for the discrimination between bacterial and viral infection, and that PCT‐guided …
safe marker for the discrimination between bacterial and viral infection, and that PCT‐guided …
Fatal pulmonary fibrosis: a post-COVID-19 autopsy case
HF Schwensen, LK Borreschmidt… - Journal of clinical …, 2021 - jcp.bmj.com
There is growing evidence of histopathological changes in autopsied individuals infected
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, data on …
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, data on …
Persistent symptoms in patients recovering from COVID-19 in Denmark
S Leth, JD Gunst, V Mathiasen… - Open Forum …, 2021 - academic.oup.com
Background Although persistent symptoms after coronavirus disease 2019 (COVID-19) are
emerging as a major complication to the infection, data on the diversity and duration of …
emerging as a major complication to the infection, data on the diversity and duration of …
Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population …
T Benfield, J Bodilsen, C Brieghel… - Clinical Infectious …, 2021 - academic.oup.com
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …